Ausbil Investment Management Ltd Grows Stake in Medpace Holdings, Inc. $MEDP

Ausbil Investment Management Ltd raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 111.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,413 shares of the company’s stock after purchasing an additional 2,852 shares during the period. Medpace comprises 1.7% of Ausbil Investment Management Ltd’s portfolio, making the stock its 24th biggest position. Ausbil Investment Management Ltd’s holdings in Medpace were worth $3,040,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in MEDP. Quent Capital LLC purchased a new position in Medpace during the 3rd quarter valued at about $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Quarry LP bought a new position in shares of Medpace during the third quarter valued at approximately $35,000. Finally, Employees Retirement System of Texas purchased a new position in Medpace during the second quarter valued at approximately $36,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price objective on the stock. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a research report on Friday, March 6th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a research report on Friday, February 13th. Finally, TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Five research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Trading Down 0.0%

NASDAQ MEDP opened at $466.60 on Friday. The firm’s fifty day simple moving average is $497.26 and its two-hundred day simple moving average is $537.33. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The firm has a market capitalization of $13.24 billion, a P/E ratio of 30.50, a P/E/G ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the prior year, the business posted $3.67 EPS. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.